In the article entitled “Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial”1 published in the December 19, 2017, issue of JAMA, an author’s name was spelled incorrectly (Jordi Bruna, MD) in the author list and a data error occurred in Table 2, in the between-group difference and confidence intervals for the year-1 survival. This article was corrected online.
References
- 1.Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. [DOI] [PMC free article] [PubMed] [Google Scholar]